


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31199066</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1582-4934</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of cellular and molecular medicine</Title>
                <ISOAbbreviation>J. Cell. Mol. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>MiR-140 modulates the inflammatory responses of Mycobacterium tuberculosis-infected macrophages by targeting TRAF6.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/jcmm.14472</ELocationID>
            <Abstract>
                <AbstractText>This study aimed to examine miR-140 expression in clinical samples from tuberculosis (TB) patients and to explore the molecular mechanisms of miR-140 in host-bacterial interactions during Mycobacterium tuberculosis (M tb) infections. The miR-140 expression and relevant mRNA expression were detected by quantitative real-time PCR (qRT-PCR); the protein expression levels were analysed by ELISA and western blot; M tb survival was measured by colony formation unit assay; potential interactions between miR-140 and the 3' untranslated region (UTR) of tumour necrosis factor receptor-associated factor 6 (TRAF6) was confirmed by luciferase reporter assay. MiR-140 was up-regulated in the human peripheral blood mononuclear cells (PBMCs) from TB patients and in THP-1 and U937 cells with M tb infection. Overexpression of miR-140 promoted M tb survival; on the other hand, miR-140 knockdown attenuated M tb survival. The pro-inflammatory cytokines including interleukin 6, tumour necrosis-α, interleukin-1β and interferon-γ were enhanced by M tb infection in THP-1 and U937 cells. MiR-140 overexpression reduced these pro-inflammatory cytokines levels in THP-1 and U937 cells with M tb infection; while knockdown of miR-140 exerted the opposite actions. TRAF6 was identified to be a downstream target of miR-140 and was negatively modulated by miR-140. TRAF6 overexpression increased the pro-inflammatory cytokines levels and partially restored the suppressive effects of miR-140 overexpression on pro-inflammatory cytokines levels in THP-1 and U937 cells with M tb infection. In conclusion, our results implied that miR-140 promoted M tb survival and reduced the pro-inflammatory cytokines levels in macrophages with M tb infection partially via modulating TRAF6 expression.</AbstractText>
                <CopyrightInformation>© 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley &amp; Sons Ltd and Foundation for Cellular and Molecular Medicine.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Xiaofei</ForeName>
                    <Initials>X</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-0912-2050</Identifier>
                    <AffiliationInfo>
                        <Affiliation>School of Life Science and Technology, Xi'an Jiaotong University, Xi'an City, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, The Third People's Hospital of Kunming City, Kunming, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Shan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, The Third People's Hospital of Kunming City, Kunming, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Tingting</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, The Third People's Hospital of Kunming City, Kunming, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liang</LastName>
                    <ForeName>Guiliang</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, The Third People's Hospital of Kunming City, Kunming, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Hongwei</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, The Third People's Hospital of Kunming City, Kunming, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pu</LastName>
                    <ForeName>Dong</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, The Third People's Hospital of Kunming City, Kunming, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peng</LastName>
                    <ForeName>Niancai</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Life Science and Technology, Xi'an Jiaotong University, Xi'an City, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>School of Mechanical Engineering, Xi'an Jiaotong University, Xi'an City, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>2017-1-S-14617</GrantID>
                    <Agency>Science and Technology Program of Kunming City</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Cell Mol Med</MedlineTA>
            <NlmUniqueID>101083777</NlmUniqueID>
            <ISSNLinking>1582-1838</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">
Mycobacterium tuberculosis
</Keyword>
            <Keyword MajorTopicYN="N">M tb survival</Keyword>
            <Keyword MajorTopicYN="N">TRAF6</Keyword>
            <Keyword MajorTopicYN="N">human peripheral blood mononuclear cells</Keyword>
            <Keyword MajorTopicYN="N">miR-140</Keyword>
            <Keyword MajorTopicYN="N">pro-inflammatory cytokines</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31199066</ArticleId>
            <ArticleId IdType="doi">10.1111/jcmm.14472</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

